Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Posted by Wayne Rhoads on Jun 16th, 2025

Mustang Bio, Inc. (NASDAQ:MBIO – Get Free Report) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 97,100 shares, an increase of 65.1% from the May 15th total of 58,800 shares. Approximately 3.3% of the company’s stock are short sold. Based on an average trading volume of 388,600 shares, the days-to-cover ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Mustang Bio from a “sell” rating to a “hold” rating in a research report on Saturday, May 24th.

Get Our Latest Research Report on MBIO

Mustang Bio Trading Down 5.1%

Shares of NASDAQ MBIO traded down $0.06 during midday trading on Monday, reaching $1.11. The company had a trading volume of 131,630 shares, compared to its average volume of 327,880. Mustang Bio has a 1 year low of $1.01 and a 1 year high of $65.00. The business’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $3.75. The stock has a market cap of $4.86 million, a P/E ratio of -0.01 and a beta of 2.24.

Mustang Bio (NASDAQ:MBIO – Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter. Analysts predict that Mustang Bio will post -35 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Mustang Bio stock. Anson Funds Management LP bought a new stake in Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 45,716 shares of the company’s stock, valued at approximately $57,000. Anson Funds Management LP owned about 1.04% of Mustang Bio as of its most recent SEC filing. Institutional investors own 9.95% of the company’s stock.

Mustang Bio Company Profile

(Get Free Report)

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.